share_log

大摩:予上海医药“增持”评级 目标价降至17港元

Morgan Stanley: Maintains "Shareholding" rating for SH PHARMA with Target Price lowered to 17 Hong Kong dollars.

Sina Hong Kong stocks ·  Dec 24, 2024 10:05

Morgan Stanley released a research report stating that after SH PHARMA (02607) announced its third quarter performance, due to weak sales, it has lowered its earnings forecast for 2024 to 2030 by 3% to 9%, and the Target Price has been reduced from HK$18.4 to HK$17, with a shareholding rating. Morgan Stanley indicated that SH PHARMA's integrated platform can provide synergy and efficiency, and there is also an increasing demand for distributing high-value patented drugs and vaccines. Additionally, the support from the Shanghai municipal government ensures the group’s leading position in the market.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment